Technavio, a company that develops over 2000 pieces of research every year and covers more than 500 technologies across 80 countries, has announced the top five leading vendors for the global breast cancer monoclonal antibodies market in their latest research report. This report also lists 11 other prominent vendors who are expected to contribute to this market’s growth between 2016-2020.
To identify the top vendors, Technavio’s market research analysts have taken into account the revenue generated by the sales of the drugs, which are expected to be launched during the forecast period.
- Branded drugs: A drug that is patent-protected and has a trade name.
- Biosimilars: A biopharmaceutical product that is similar to the US FDA-approved biologic and exhibits similar safety and effectiveness.
This Technavio report, under medical devices vertical, is based on the synthesis, analysis, and interpretation of information about the breast cancer monoclonal antibodies market collected from specialized sources. The analysts have derived insights using a mix of primary and secondary research with an aim to provide a holistic picture of the market.
Click here to request a free sample of this report
Competitive vendor landscape
The increase in factors such as product extensions, technological innovations, and an increase in the number of mergers and acquisitions, results in increase of competitiveness in the breast cancer monoclonal antibodies market. The pharmaceutical companies that are looking forward to grow in this market can adopt these strategies.
“Emerging economies such as BRIC countries are increasingly becoming aware of the importance of drug designations, such as the orphan drug designation, and are thereby working on developing regulatory protocols required to award these designations. They are also working toward providing incentives such as reimbursements to pharmaceutical manufacturers, which may encourage research on mAbs. These factors paired with the rising political and regulatory reforms are set to increase the market revenue of emerging markets during the forecast period,” says Barath Palada, a lead analyst at Technavio for research on medical devices.
Top five vendors in the breast cancer monoclonal antibodies market space
Roche
Roche is one of the dominant vendors in the global breast cancer monoclonal antibodies market. The company focuses on expanding the indications of its existing mAbs and gaining approvals for new products. For instance, the approval of Kadcyla and Perjeta could provide substantial growth opportunities. The company focuses on identifying and developing new cancer treatment drugs by collaborating with other top vendors.
Some of the key products offered are: Avastin, Perjeta, Kadcyla, and Herceptin.
Amgen
Amgen deals with developing and manufacturing human therapeutics. The therapeutic areas it concentrates on are cancer, bone disease, kidney disease, and rheumatoid arthritis. Xgeva is a key drug manufactured by Amgen that saw a strong sale in the market. In FY2015, the company reported revenue of $21.66 billion and invested $3.91 billion in R&D. Xgeva (denosumab) is one of the key products offered by the company.
Mylan
Mylan manufactures, licenses and markets generic and specialty pharmaceutical products in dermatology and cardiovascular therapeutic areas. The company offers biosimilar products across indications such as cancer. One of the strategies followed by the company is to invest more on research and development to come up with new biosimilars. Trastuzumab is one of the key products offered by the company.
Biocad
Biocad focuses on developing and manufacturing biological products and generic biotechnological drugs. The drugs developed by Biocad are mainly for the purpose of autoimmune diseases, hematology, reproductive health, oncology, and viral infections.
Synta Pharmaceuticals
Synta Pharmaceuticals focuses on analyzing, developing and commercializing small molecule drugs. The drugs developed by Synta Pharmaceuticals are mainly for the purpose of treatment of chronic inflammatory diseases and cancer in addition to other major medical conditions.
Some of the other prominent vendors in this market include Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industries, and Teva Pharmaceuticals.
A more detailed analysis is available in the Technavio report, Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020. Technavio also customizes reports by other regions and specific segments upon request.
To read more press releases- click here.
Browse related reports:
- Global Leukemia Therapeutics Market 2016-2020
- Global Intracranial Pressure Monitoring Market 2016-2020
- Global Solid Tumors Drugs Market 2016-2020
- Global Chronic Lymphocytic Leukemia Therapeutics Market 2016-2020
- Global Monoclonal Antibodies Market 2016-2020
- Global Cancer Immunotherapies Market 2016-2020
For any assistance or query, please contact our media team at:
US: +1 630 333 9501
UK: +44 208 123 1770
